Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone

Joy A. Phillips, Edward L. Morgan, Yuxiang Dong, Garry T. Cole, Cody McMahan, Chiung Yu Hung, Sam Sanderson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This paper describes a method for a single-step, site-specific conjugation of bioactive peptides to proteins that exploits the monitoring advantages provided by the unique UV signature absorbance of a bis-arylhydrazone. The utility of this method is demonstrated by the conjugation of a decapeptide molecular adjuvant, YSFKDMP(MeL)aR (EP67), to two test proteins, ovalbumin (OVA) and bovine serum albumin (BSA), and to proteins expressed on intact influenza virons and fungal arthroconidia (spores) of Coccidioides. Conjugation is accomplished with a version of EP67 in which its N-terminus is modified with succinimidyl-4-benzoylhydrazino-nicotinamide (S4BHyNic) (peptide 7), thus enabling conjugation to these large entities via formation of amide bonds with surface-exposed amino groups. The presence of the strongly absorbing bis-arylhydrazone S4BHyNic (ε354 nm = 29 000 L mol-1 cm-1) allows for determination of EP67-to-protein molar substitution ratios (MSR), which are in good agreement with the MSRs determined by amino acid analysis. Conjugation to OVA does not compromise the ability of EP67 to engage C5a receptor bearing antigen presenting cells (APC) as measured by the EP67-mediated release of interleukin-6 (IL-6) from APCs. Mice immunized with the resulting OVA-EP67 vaccine conjugate produce high serum titers of OVA-specific IgG antibodies relative to OVA alone. Also, the conjugation of EP67 does not affect the surface integrity of influenza virons or the biological viability of Coccidioides spores. This method of conjugating bioactive peptides to proteins and other large biological entities may represent a convenient and effective way of generating various bioconjugates for use in mechanistic studies or novel therapeutic entities such as EP67-containing vaccines.

Original languageEnglish (US)
Pages (from-to)1950-1957
Number of pages8
JournalBioconjugate Chemistry
Volume20
Issue number10
DOIs
StatePublished - Oct 21 2009

Fingerprint

Ovalbumin
Peptides
Proteins
Coccidioides
Vaccines
Niacinamide
Human Influenza
Bearings (structural)
Anaphylatoxin C5a Receptor
Conjugate Vaccines
Fungal Spores
Antigen-Presenting Cells
Bovine Serum Albumin
Spores
Amides
Antibodies
Amino acids
Interleukin-6
Substitution reactions
Immunoglobulin G

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

Phillips, J. A., Morgan, E. L., Dong, Y., Cole, G. T., McMahan, C., Hung, C. Y., & Sanderson, S. (2009). Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. Bioconjugate Chemistry, 20(10), 1950-1957. https://doi.org/10.1021/bc9002794

Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. / Phillips, Joy A.; Morgan, Edward L.; Dong, Yuxiang; Cole, Garry T.; McMahan, Cody; Hung, Chiung Yu; Sanderson, Sam.

In: Bioconjugate Chemistry, Vol. 20, No. 10, 21.10.2009, p. 1950-1957.

Research output: Contribution to journalArticle

Phillips, JA, Morgan, EL, Dong, Y, Cole, GT, McMahan, C, Hung, CY & Sanderson, S 2009, 'Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone', Bioconjugate Chemistry, vol. 20, no. 10, pp. 1950-1957. https://doi.org/10.1021/bc9002794
Phillips, Joy A. ; Morgan, Edward L. ; Dong, Yuxiang ; Cole, Garry T. ; McMahan, Cody ; Hung, Chiung Yu ; Sanderson, Sam. / Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. In: Bioconjugate Chemistry. 2009 ; Vol. 20, No. 10. pp. 1950-1957.
@article{38fbcd62251c41f794d3f29bf94c0d3a,
title = "Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone",
abstract = "This paper describes a method for a single-step, site-specific conjugation of bioactive peptides to proteins that exploits the monitoring advantages provided by the unique UV signature absorbance of a bis-arylhydrazone. The utility of this method is demonstrated by the conjugation of a decapeptide molecular adjuvant, YSFKDMP(MeL)aR (EP67), to two test proteins, ovalbumin (OVA) and bovine serum albumin (BSA), and to proteins expressed on intact influenza virons and fungal arthroconidia (spores) of Coccidioides. Conjugation is accomplished with a version of EP67 in which its N-terminus is modified with succinimidyl-4-benzoylhydrazino-nicotinamide (S4BHyNic) (peptide 7), thus enabling conjugation to these large entities via formation of amide bonds with surface-exposed amino groups. The presence of the strongly absorbing bis-arylhydrazone S4BHyNic (ε354 nm = 29 000 L mol-1 cm-1) allows for determination of EP67-to-protein molar substitution ratios (MSR), which are in good agreement with the MSRs determined by amino acid analysis. Conjugation to OVA does not compromise the ability of EP67 to engage C5a receptor bearing antigen presenting cells (APC) as measured by the EP67-mediated release of interleukin-6 (IL-6) from APCs. Mice immunized with the resulting OVA-EP67 vaccine conjugate produce high serum titers of OVA-specific IgG antibodies relative to OVA alone. Also, the conjugation of EP67 does not affect the surface integrity of influenza virons or the biological viability of Coccidioides spores. This method of conjugating bioactive peptides to proteins and other large biological entities may represent a convenient and effective way of generating various bioconjugates for use in mechanistic studies or novel therapeutic entities such as EP67-containing vaccines.",
author = "Phillips, {Joy A.} and Morgan, {Edward L.} and Yuxiang Dong and Cole, {Garry T.} and Cody McMahan and Hung, {Chiung Yu} and Sam Sanderson",
year = "2009",
month = "10",
day = "21",
doi = "10.1021/bc9002794",
language = "English (US)",
volume = "20",
pages = "1950--1957",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone

AU - Phillips, Joy A.

AU - Morgan, Edward L.

AU - Dong, Yuxiang

AU - Cole, Garry T.

AU - McMahan, Cody

AU - Hung, Chiung Yu

AU - Sanderson, Sam

PY - 2009/10/21

Y1 - 2009/10/21

N2 - This paper describes a method for a single-step, site-specific conjugation of bioactive peptides to proteins that exploits the monitoring advantages provided by the unique UV signature absorbance of a bis-arylhydrazone. The utility of this method is demonstrated by the conjugation of a decapeptide molecular adjuvant, YSFKDMP(MeL)aR (EP67), to two test proteins, ovalbumin (OVA) and bovine serum albumin (BSA), and to proteins expressed on intact influenza virons and fungal arthroconidia (spores) of Coccidioides. Conjugation is accomplished with a version of EP67 in which its N-terminus is modified with succinimidyl-4-benzoylhydrazino-nicotinamide (S4BHyNic) (peptide 7), thus enabling conjugation to these large entities via formation of amide bonds with surface-exposed amino groups. The presence of the strongly absorbing bis-arylhydrazone S4BHyNic (ε354 nm = 29 000 L mol-1 cm-1) allows for determination of EP67-to-protein molar substitution ratios (MSR), which are in good agreement with the MSRs determined by amino acid analysis. Conjugation to OVA does not compromise the ability of EP67 to engage C5a receptor bearing antigen presenting cells (APC) as measured by the EP67-mediated release of interleukin-6 (IL-6) from APCs. Mice immunized with the resulting OVA-EP67 vaccine conjugate produce high serum titers of OVA-specific IgG antibodies relative to OVA alone. Also, the conjugation of EP67 does not affect the surface integrity of influenza virons or the biological viability of Coccidioides spores. This method of conjugating bioactive peptides to proteins and other large biological entities may represent a convenient and effective way of generating various bioconjugates for use in mechanistic studies or novel therapeutic entities such as EP67-containing vaccines.

AB - This paper describes a method for a single-step, site-specific conjugation of bioactive peptides to proteins that exploits the monitoring advantages provided by the unique UV signature absorbance of a bis-arylhydrazone. The utility of this method is demonstrated by the conjugation of a decapeptide molecular adjuvant, YSFKDMP(MeL)aR (EP67), to two test proteins, ovalbumin (OVA) and bovine serum albumin (BSA), and to proteins expressed on intact influenza virons and fungal arthroconidia (spores) of Coccidioides. Conjugation is accomplished with a version of EP67 in which its N-terminus is modified with succinimidyl-4-benzoylhydrazino-nicotinamide (S4BHyNic) (peptide 7), thus enabling conjugation to these large entities via formation of amide bonds with surface-exposed amino groups. The presence of the strongly absorbing bis-arylhydrazone S4BHyNic (ε354 nm = 29 000 L mol-1 cm-1) allows for determination of EP67-to-protein molar substitution ratios (MSR), which are in good agreement with the MSRs determined by amino acid analysis. Conjugation to OVA does not compromise the ability of EP67 to engage C5a receptor bearing antigen presenting cells (APC) as measured by the EP67-mediated release of interleukin-6 (IL-6) from APCs. Mice immunized with the resulting OVA-EP67 vaccine conjugate produce high serum titers of OVA-specific IgG antibodies relative to OVA alone. Also, the conjugation of EP67 does not affect the surface integrity of influenza virons or the biological viability of Coccidioides spores. This method of conjugating bioactive peptides to proteins and other large biological entities may represent a convenient and effective way of generating various bioconjugates for use in mechanistic studies or novel therapeutic entities such as EP67-containing vaccines.

UR - http://www.scopus.com/inward/record.url?scp=70350342886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350342886&partnerID=8YFLogxK

U2 - 10.1021/bc9002794

DO - 10.1021/bc9002794

M3 - Article

VL - 20

SP - 1950

EP - 1957

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 10

ER -